Crossmark

Efficacy and safety of sacituzumab govitecan Trop-2-targeted antibody-drug conjugate in solid tumors and UGT1A1*28 polymorphism: a systematic review and meta-analysis

Crossref DOI link: https://doi.org/10.1038/s44276-024-00106-1

Published Online: 2024-11-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sultana, Rehena

Chen, Sylvia

Lim, Elaine Hsuen

Dent, Rebecca

Chowbay, Balram
Funding

Funding for this research was provided by:

National Medical Research Council (MOH-000984)

National Medical Research Council (MOH-000984)
License Information

Text and Data Mining valid from 2024-11-11

Version of Record valid from 2024-11-11
More Information

Article History

Received: 6 May 2024

Revised: 6 September 2024

Accepted: 3 October 2024

First Online: 11 November 2024

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below